About Botanix Pharmaceuticals
Botanix Pharmaceuticals (ASX:BOT) is a dermatology company focused on the development and commercialization of innovative and effective topical treatments for a range of serious skin conditions. The company has a portfolio of products in clinical development, including its lead product, Sofpironium Bromide, which is currently in Phase 3 clinical trials for the treatment of primary axillary hyperhidrosis (excessive underarm sweating). Botanix is also developing other products for the treatment of atopic dermatitis, rosacea, and acne. The company's products are based on a proprietary technology platform called Australasian Botanical Products (ABP), which harnesses the power of natural plant extracts to develop new and effective treatments for skin conditions.
Snapshot
Operations
Products and/or services of Botanix Pharmaceuticals
- Sofpironium Bromide for Primary Axillary Hyperhidrosis: Botanix is developing Sofpironium Bromide, a novel topical treatment for primary axillary hyperhidrosis (excessive underarm sweating). The company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for Sofpironium Bromide, and a decision is expected in Q3 2023.
- BTX-1503 for Moderate to Severe Acne: Botanix is developing BTX-1503, a novel topical treatment for moderate to severe acne. The company has completed a Phase 2 clinical trial of BTX-1503, and the results were positive. Botanix is planning to initiate a Phase 3 clinical trial of BTX-1503 in 2023.
- BTX-1702 for Rosacea: Botanix is developing BTX-1702, a novel topical treatment for rosacea. The company has completed a Phase 1b/2 clinical trial of BTX-1702, and the results were positive. Botanix is planning to initiate a Phase 3 clinical trial of BTX-1702 in 2023.
- BTX-1204A for Atopic Dermatitis: Botanix is developing BTX-1204A, a novel topical treatment for atopic dermatitis. The company has completed a canine proof-of-concept study for BTX-1204A, and the results were positive. Botanix is planning to initiate a Phase 1 clinical trial of BTX-1204A in 2023.
- BTX-1801 for Antimicrobial Applications: Botanix is developing BTX-1801, a novel topical antimicrobial agent. The company has completed a Phase 2a clinical trial of BTX-1801, and the results were positive. Botanix is planning to initiate a Phase 2b clinical trial of BTX-1801 in 2023.
Botanix Pharmaceuticals executive team
- Mr. Vincent P. IppolitoMD & Executive Chairman
- Dr. Howie McKibbonChief Executive Officer
- Mr. Graeme MorisseyChief Financial Officer
- Mr. Chris LesovitzChief Financial Officer of United States of America
- Dr. Boris Meyerson Ph.D.Chief Business Officer
- Mr. David MorganHead of Corporate Affairs
- Mr. Kevin WojciechowskiHead of HCP Marketing & Sales Training
- Mr. Andrew BickleyJoint Company Secretary
- Mr. Darin Van ArsdaleDirector of Sales Operations